{"product_id":"merit-pestle-analysis","title":"Merit Medical PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political, economic, social, technological, legal, and environmental forces are shaping Merit Medical's strategic outlook in our concise PESTLE snapshot—ideal for investors and strategists who need quick, actionable context. Purchase the full PESTLE analysis to unlock detailed risk assessments, trend forecasts, and practical recommendations you can use immediately to inform decisions and outmaneuver competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing US-China trade tensions have raised tariff uncertainty that affects medical device supply chains; tariffs and export controls contributed to a 6–12% increase in component costs for some manufacturers in 2023–2024, pressuring Merit Medical’s margins.\u003c\/p\u003e\n\u003cp\u003eShifting tariff structures and regional agreements (USMCA, CPTPP accession talks) alter input and finished-goods costs, with ocean freight volatility—up 40% in 2021–2022 and normalizing but still elevated—adding to expense variability.\u003c\/p\u003e\n\u003cp\u003eStrategic diversification of manufacturing—Merit’s 2024 investments expanding capacity in Ireland and Mexico—reduces exposure to sudden policy shifts in major markets and helps stabilize lead times and cost predictability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment-led shifts in reimbursement, notably CMS's 2024 Inpatient Prospective Payment updates and expansion of value-based programs covering over 35% of Medicare payments, directly reduce hospital purchasing power and prioritize cost-effective disposables. Political pressure to cut healthcare spending has driven value-based pricing mandates that compress margins for single-use devices, where Merit reported 2024 disposable product revenue of roughly $1.1 billion. Merit must align product value propositions with legislative priorities on affordability and procedural efficiency to protect uptake and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal regulatory harmonization can lower compliance costs for Merit Medical, which reported $1.56B revenue in FY2024, by streamlining approvals across markets but may also impose EU MDR-like requirements that raise R\u0026amp;D spend; FDA collaboration with EMA and ICH shortens time-to-market—recent joint guidances cut review times by ~15% in pilot programs—while political instability in emerging markets (e.g., 2024 GDP growth volatility: Latin America 3.1%, Sub-Saharan Africa 3.5%) influences expansion risk and capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment healthcare budgets and fiscal policies shape public funding for infrastructure and elective procedures; global public health spending reached an estimated $9.3 trillion in 2024, with OECD countries averaging 8.6% of GDP.\u003c\/p\u003e\n\u003cp\u003eIn socialized systems, 2024 austerity pushed procurement delays and preference for lower-cost domestic suppliers, reducing import med-tech spend by ~4–6% in some EU markets.\u003c\/p\u003e\n\u003cp\u003eMerit Medical’s demand depends on steady public investment in cardiology and oncology—markets where public hospitals accounted for roughly 60% of device purchases in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic health spend $9.3T (2024)\u003c\/li\u003e\n\u003cli\u003eOECD avg 8.6% GDP\u003c\/li\u003e\n\u003cli\u003eEU med-tech import spend down 4–6% in austerity\u003c\/li\u003e\n\u003cli\u003ePublic hospitals ~60% of cardiology\/oncology device buys (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaxation and Corporate Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChanges in US federal corporate tax rates and OECD international tax reforms (e.g., 15% global minimum tax) can materially affect Merit Medical’s FY2025 net income and free cash flow, altering effective tax rate assumptions used in valuations; Merit reported $17.2M tax expense in FY2024, highlighting sensitivity to rate shifts.\u003c\/p\u003e\n\u003cp\u003ePolitical moves to impose excise taxes on medical device makers could raise COGS and SG\u0026amp;A, squeezing margins—device tax proposals historically targeted up to 2.3% of sales, which on Merit’s $1.0B revenue (TTM 2024) would imply ~$23M incremental cost.\u003c\/p\u003e\n\u003cp\u003eLegislative changes to R\u0026amp;D tax credits influence Merit’s R\u0026amp;D capitalization and cash tax outflows; expansion of credits (e.g., increase from 14% to proposed 20% rates in some bills) could materially improve after-tax cash available for product development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOECD 15% global minimum tax impacts effective tax rate planning\u003c\/li\u003e\n\u003cli\u003e2.3% device excise tax on $1.0B revenue ≈ $23M annual cost\u003c\/li\u003e\n\u003cli\u003eFY2024 tax expense $17.2M — indicates tax sensitivity\u003c\/li\u003e\n\u003cli\u003eStronger R\u0026amp;D credits could reduce cash tax and fund innovation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade, tariffs and taxes squeeze margins—$1.56B revenue, $1.1B disposables in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrade tensions, tariffs and freight volatility raised component costs ~6–12% in 2023–24; Merit’s 2024 Ireland\/Mexico capacity reduces policy exposure. CMS payment shifts and value-based mandates (35%+ Medicare value payments) compress margins on disposables—2024 disposable revenue ≈ $1.1B. OECD 15% minimum tax and potential 2.3% device excise pose tax\/COGS risks; FY2024 revenue $1.56B, tax expense $17.2M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$1.56B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisposable revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTax expense\u003c\/td\u003e\n\u003ctd\u003e$17.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff impact\u003c\/td\u003e\n\u003ctd\u003e6–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Merit Medical across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends, actionable insights for executives and investors, and forward-looking scenario inputs—formatted for easy inclusion in plans, decks, or reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Merit Medical's PESTLE into a concise, shareable summary that surfaces key external risks and opportunities for rapid decision-making in meetings or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising raw material, energy and labor costs compressed Merit Medicals gross margins for disposables; commodity and resin prices rose ~18% in 2024 and US industrial energy CPI rose 9.6% year-over-year, squeezing margins on high-volume items.\u003c\/p\u003e\n\u003cp\u003ePassing costs to hospitals is constrained as US hospital operating margins averaged 2.8% in 2024, forcing Merit to absorb increases or seek price concessions.\u003c\/p\u003e\n\u003cp\u003eEconomic volatility in 2024–2025 makes disciplined cost management essential: Merit reported 6.5% productivity improvements in 2024 and prioritized automation and sourcing to protect profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a global medical device maker, Merit Medical faces notable currency risk: in 2024 foreign exchange movements trimmed international revenue by an estimated 2.1% after translation, with EUR\/USD volatility ±6% and CNY\/USD swings up to ±8% year-over-year affecting reported sales.\u003c\/p\u003e\n\u003cp\u003eLarge moves in the euro, yuan or yen can compress local margins and force price adjustments versus competitors; in 2024 Merit cited FX as a key driver of a mid-single-digit impact on operating income.\u003c\/p\u003e\n\u003cp\u003eMerit mitigates exposure through forward hedges covering a portion of forecasted flows and by regionalizing production—localized manufacturing in Europe and APAC reduced translation sensitivity and import cost pressure in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe current higher interest rate environment—US Fed funds at 5.25–5.50% as of Dec 2024—raises Merit Medical’s cost of debt, increasing financing costs for acquisitions and capex and potentially constraining M\u0026amp;A; Moody’s Baa corporate yields ~5.1% in 2024 versus ~3% in 2021, making large leveraged deals more expensive. A stabilizing rate path would improve predictability for long‑term investments in manufacturing capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Economic Growth Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe demand for diagnostic and therapeutic procedures tracks with economic health; global GDP growth slowed to about 3.0% in 2023 and IMF projects 3.0–3.2% for 2024–25, which can constrain elective procedure volumes and device purchases.\u003c\/p\u003e\n\u003cp\u003eMedical devices show relative resilience, but a sharp downturn (eg 2008–09) historically cut elective procedures by double digits; Merit’s sales growth hinges on recovery pace and rising middle-class healthcare spending in EMs where middle-class population is projected to add ~1.0 billion people by 2030.\u003c\/p\u003e\n\u003cp\u003eMerit’s exposure to emerging markets makes expansion dependent on GDP per capita gains and healthcare spend growth, with global health expenditure reaching ~10% of GDP in high-income countries vs 5% in low-income markets, affecting procedure mix and ASPs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIMF global GDP ~3.0% (2024–25 forecast)\u003c\/li\u003e\n\u003cli\u003eMiddle-class +~1.0B by 2030 (Emerging Markets)\u003c\/li\u003e\n\u003cli\u003eHealth spend: ~10% GDP (high-income) vs ~5% (low-income)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpshortages in skilled manufacturing labor and specialized sales forces raise wage pressure job vacancies averaged merit medical to absorb higher costs face production delays.\u003e\n\u003cpmerit must boost retention and invest in automation capital expenditure rose industry-wide as firms automated to cut labor intensity improve throughput.\u003e\n\u003cpavailability of biomedical engineers is critical engineering graduates grew in yet demand medtech outpaces supply threatening merit innovation pipeline and r velocity.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturing vacancies ~642,000 (2024)\u003c\/li\u003e\n\u003cli\u003eIndustry capex +8% (2024)\u003c\/li\u003e\n\u003cli\u003eBiomedical engineering grads +3% (2023)\u003c\/li\u003e\n\u003cli\u003eHigher wage competition increases COGS and delays time-to-market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pavailability\u003e\u003c\/pmerit\u003e\u003c\/pshortages\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising input \u0026amp; energy costs squeeze margins amid weak demand, FX drag, and higher rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising input costs and energy (resin +18% in 2024; US industrial energy CPI +9.6%) compressed margins while hospital margins (2.8% in 2024) limit price pass-through; FX trimmed international revenue ~2.1% in 2024; Fed funds 5.25–5.50% (Dec 2024) raised cost of debt; IMF GDP ~3.0% (2024–25) moderates procedure demand; manufacturing vacancies ~642,000 (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResin\/commodity change\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS industrial energy CPI\u003c\/td\u003e\n\u003ctd\u003e+9.6% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital operating margin\u003c\/td\u003e\n\u003ctd\u003e2.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX revenue impact\u003c\/td\u003e\n\u003ctd\u003e-2.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMF global GDP\u003c\/td\u003e\n\u003ctd\u003e~3.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS manufacturing vacancies\u003c\/td\u003e\n\u003ctd\u003e~642,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMerit Medical PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Merit Medical PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751900688761,"sku":"merit-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/merit-pestle-analysis.png?v=1772235895","url":"https:\/\/growthsharematrix.com\/products\/merit-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}